AOD-9604 Manufacturing, Supply & Shortage History: What Women Need to Know

What Is AOD-9604 and How Does It Work?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the carboxy-terminal fragment of human growth hormone, spanning residues 176 through 191. It was designed to isolate the fat-mobilizing activity of growth hormone without triggering the anabolic or insulin-desensitizing effects tied to full GH-receptor activation.

The core insight came from Heffernan et al. (Endocrinology, 2001), who demonstrated in animal models that this fragment retains lipolytic and antilipogenic activity. Critically, the peptide did so without stimulating IGF-1 production or activating the classical GH receptor pathway, which is the mechanism responsible for GH-related glucose dysregulation and organ growth.

The Receptor Story

Full-length growth hormone binds the GH receptor (GHR) at two sites. AOD-9604 does not bind GHR in the same way. Instead, early research proposed it interacts with a separate, not yet fully characterized receptor or membrane target to stimulate beta-3 adrenergic-like lipolysis in adipocytes. This distinction matters clinically: patients using full-length GH often see rising fasting glucose and insulin resistance, whereas animal and early Phase I human data did not reproduce that metabolic penalty with the fragment.

Why Women's Fat Physiology Is Relevant Here

Women store fat differently than men at every life stage. During reproductive years, estrogen directs preferential subcutaneous gluteofemoral deposition. After menopause, estrogen withdrawal drives a shift toward visceral and abdominal adiposity, a pattern associated with increased cardiometabolic risk. This menopausal fat redistribution is one reason postmenopausal women inquire about AOD-9604 more than any other demographic in compounding-focused telehealth. Women with PCOS also carry disproportionate visceral fat burden independent of BMI, which drives a second cohort of interest.

The evidence gap here is real and must be stated plainly: every published lipolysis study using AOD-9604 was conducted in rodent models or in male-predominant Phase I/II human cohorts. No peer-reviewed trial has stratified outcomes by sex, hormonal status, or menopausal stage. What compounding prescribers apply to perimenopausal women is extrapolated from male-weighted or animal data.

AOD-9604 Manufacturing: How the Peptide Is Made

AOD-9604 has never been approved by the FDA as a finished pharmaceutical product. That means there is no commercial manufacturer producing it under an approved New Drug Application (NDA) or Biologics License Application (BLA). Every vial dispensed in the United States originates from a 503A compounding pharmacy, and the quality of that vial depends entirely on where it was made.

The 503A Compounding Framework

Under 21 U.S.C. § 503A, a 503A pharmacy may compound a drug for an identified individual patient based on a valid prescription. These pharmacies are not required to file an NDA, but they must use active pharmaceutical ingredients (APIs) sourced from FDA-registered facilities and follow USP standards for sterile preparations.

For AOD-9604, the API is synthesized by solid-phase peptide synthesis (SPPS), a process in which amino acids are assembled sequentially on a resin support. The finished peptide is then cleaved, purified by high-performance liquid chromatography (HPLC), and lyophilized (freeze-dried) into a powder. The compounding pharmacy reconstitutes this powder with bacteriostatic water to produce the injectable solution dispensed to patients.

Quality Signals That Actually Matter

Not all compounding pharmacies perform equivalent quality control. When evaluating a pharmacy for peptide compounding, the minimum acceptable quality markers are:

• Certificate of Analysis (CoA) from an independent third-party laboratory confirming peptide identity by mass spectrometry and purity by HPLC (>98% purity is the accepted standard for injectable peptides)
• Sterility testing per USP <71>
• Endotoxin testing per USP <85>
• Documentation that the API supplier is FDA-registered

The FDA has issued warning letters to compounding pharmacies dispensing peptide products without adequate sterility documentation. A woman sourcing AOD-9604 should ask her prescriber for the pharmacy's most recent CoA before filling any prescription.

The Bulk Drug Substance List Problem

This is where supply gets structurally complicated. The FDA maintains a list of bulk drug substances that may be used in compounding. AOD-9604 is not on the FDA's 503A Bulks List as an approved nominee. Its regulatory status has been, and remains, contested.

In 2020 and again in 2023, the FDA signaled heightened scrutiny of peptides used in compounding that lack adequate clinical evidence or that had previously been studied as investigational new drugs (INDs). AOD-9604 was studied under an IND by Metabolic Pharmaceuticals Ltd. In the early 2000s through Phase IIb trials in obese adults before the program was discontinued after the primary endpoint was not met in the Phase IIb METRO trial. Once a compound has been part of a clinical investigation, the FDA takes the position that it cannot be compounded under 503A without additional regulatory review. This interpretation has created ongoing legal and practical tension in the compounding space.

AOD-9604 Shortage History: A Timeline

AOD-9604 supply in the U.S. Compounding market has not been continuous. It has moved through at least three identifiable disruption cycles since 2018.

The following framework for understanding peptide compounding shortages draws on the regulatory history documented by the FDA and the structure of the compounding supply chain, synthesized here for clinical use.

Cycle 1, 2018-2019: API sourcing disruptions. The majority of peptide APIs used by U.S. Compounders are synthesized overseas, primarily in China and India, then imported. In 2018-2019, several large Chinese API manufacturers faced manufacturing shutdowns tied to environmental enforcement actions by Chinese regulators. This constrained raw peptide supply across multiple compounds simultaneously, including AOD-9604, BPC-157, and TB-500. Pharmacies that had not secured adequate inventory experienced weeks-long dispensing gaps.

Cycle 2, 2020-2021: FDA enforcement escalation. The FDA's 2020 guidance on outsourcing facilities and bulk drug substances created compliance uncertainty. Several larger 503B outsourcing facilities that had been supplying AOD-9604 to 503A pharmacies ceased production while awaiting regulatory clarity. 503B facilities serve multiple prescribers and pharmacies, so their exit from the market had an outsized supply impact.

Cycle 3, 2023-2024: Semaglutide-era enforcement spillover. The FDA's aggressive enforcement of GLP-1 compounding rules following the semaglutide shortage designation drew fresh regulatory attention to the broader peptide compounding market. Several pharmacy inspections in 2023 resulted in voluntary holds on peptide product lines, including AOD-9604, while pharmacies updated their sterility documentation. Supply recovered partially by mid-2024, but remained inconsistent across regions.

What Shortage Means for a Woman on AOD-9604

Abrupt discontinuation of AOD-9604 does not carry the withdrawal risks associated with hormonal therapies or opioids. Animal data suggests lipolytic effects are reversible, meaning adipose tissue returns toward baseline over weeks if the peptide is stopped. Still, women in the middle of a prescribed course who face a supply gap should know:

• There is no equivalent FDA-approved alternative that replicates AOD-9604's proposed mechanism
• Full-length growth hormone (somatropin) carries a meaningfully different risk profile, including glucose dysregulation and fluid retention, and is not an appropriate substitution
• Resuming after a gap does not appear to require dose titration, based on pharmacokinetic principles for short peptides, though direct human restart data does not exist

Sex-Specific Pharmacokinetics: What Little We Know

Peptide pharmacokinetics in women differ from those in men in ways that matter for dosing. Women generally have higher total body fat percentage and lower lean mass per kilogram of body weight, which affects volume of distribution for lipophilic compounds. Short peptides like AOD-9604 are predominantly hydrophilic and degrade rapidly by serum proteases, with an estimated half-life under 30 minutes in animal models. This makes accumulation unlikely, but it also means the therapeutic window per injection is narrow.

The menstrual cycle adds another layer of complexity. Estrogen upregulates growth hormone pulsatility and enhances GH sensitivity in peripheral tissues. In women during the follicular phase, endogenous GH pulses are more frequent and of larger amplitude than during the luteal phase. Whether exogenous AOD-9604 interacts with this cyclical variation has never been studied. Women using AOD-9604 during reproductive years may experience variable responses across their cycle with no published data to predict this.

Postmenopausal women have blunted GH pulsatility and lower IGF-1 levels relative to premenopausal peers. If AOD-9604's lipolytic activity has any dependence on background GH tone (the evidence does not clarify this), postmenopausal women may respond differently. Again, this is extrapolation. The trials were not designed to answer this question.

Women with PCOS present a distinct physiological context. PCOS is associated with altered GH secretion patterns, with some studies showing reduced GH pulse amplitude and others showing elevated GH sensitivity. The interaction between AOD-9604 and the PCOS hormonal environment is entirely unstudied.

Pregnancy, Lactation, and Contraception

AOD-9604 is contraindicated in pregnancy. No human pregnancy safety data exists. No animal reproductive toxicology studies have been published in peer-reviewed literature. Because the peptide is designed to manipulate adipose metabolism and was derived from a hormone (GH) that plays roles in fetal growth and placental function, the theoretical risk of interference with normal fetal development cannot be excluded.

Growth hormone and its downstream mediator IGF-1 are required for normal fetal growth. While AOD-9604 does not activate the classical GH receptor, its downstream effects on adipocyte signaling in a developing fetus are unknown. Invoking the precautionary principle is appropriate here, not optional.

If you are trying to conceive, stop AOD-9604 before your first attempted conception cycle. Given the short half-life (estimated under 30 minutes), peptide clearance is rapid and a washout period of 48-72 hours is theoretically sufficient, but without human data, a 30-day washout before active conception attempts is a reasonable conservative recommendation.

Lactation: No data exists on AOD-9604 transfer into human breast milk. Peptides are generally degraded in the infant GI tract and have poor oral bioavailability, which would limit systemic infant exposure even if transfer occurs. However, "probably low risk" based on pharmacological reasoning is not equivalent to "studied and confirmed safe." Avoid use while breastfeeding.

Contraception: Women of reproductive age prescribed AOD-9604 should use reliable contraception during use. No specific drug interactions with hormonal contraceptives have been identified, but because combined oral contraceptives affect GH secretion and IGF-1 levels, the hormonal context is relevant and warrants disclosure to the prescribing clinician.

Who This May Be Right For and Who Should Avoid It

Given the current evidence base and manufacturing field, AOD-9604 sits in a narrow clinical space.

Potentially Appropriate Candidates

Women who may be reasonable candidates for a monitored trial of AOD-9604 include:

• Postmenopausal women with documented visceral adiposity who have plateaued on lifestyle interventions and who are not candidates for or have not responded to GLP-1 receptor agonists
• Women with PCOS and central adiposity in whom metabolic interventions are being systematically tried under endocrine supervision
• Women who have completed childbearing and are using reliable contraception, under the care of a prescriber at a practice with access to a verified, high-quality 503A compounding pharmacy

Who Should Not Use AOD-9604

• Anyone currently pregnant or planning conception within the next three months
• Women breastfeeding
• Women with a history of any cancer, given theoretical concerns about growth-factor pathway manipulation (IGF-1 independent; still not studied in oncology populations)
• Women with active acromegaly or GH-secreting tumors
• Anyone sourcing peptides from unverified online vendors without a prescription, where purity and sterility cannot be confirmed

What to Ask Your Prescriber and Pharmacy

The compounding supply situation means that the quality of what you receive depends heavily on who dispenses it. Before filling a prescription for AOD-9604, ask:

1. Which pharmacy is being used, and is it PCAB-accredited or state-board inspected within the last 12 months?
2. Can the pharmacy provide a current Certificate of Analysis showing mass-spec confirmed identity and HPLC purity >98%?
3. Has the pharmacy's AOD-9604 batch been tested for sterility and endotoxins per USP standards?
4. Is there a current supply of your specific dose formulation, or is there a waitlist?
5. What is the prescriber's monitoring plan (labs, body composition assessment, follow-up interval)?

A prescriber who cannot answer questions 1 through 3 is not operating at an adequate standard of care for a compounded sterile injectable.

The Future of AOD-9604 Supply: Regulatory Signals

The FDA's ongoing review of the 503A bulk drug substance nominations will determine whether AOD-9604 can be legally compounded long-term. There are three plausible outcomes:

Outcome A: Inclusion on the 503A bulks list. This would stabilize the legal basis for compounding and likely improve supply chain investment from pharmacies. It would not create an FDA-approved drug.

Outcome B: Exclusion from the 503A bulks list. This would effectively end legal compounding of AOD-9604 in the U.S. For individual patients. Existing prescriptions would need to be discontinued and alternative strategies pursued.

Outcome C: Continued regulatory limbo. The current state. Pharmacies continue to compound with varying degrees of legal confidence, supply remains intermittent, and patients bear the uncertainty.

The FDA has not indicated a firm timeline for resolving AOD-9604's status. Women currently using or considering this peptide should factor this regulatory uncertainty into their decision-making and maintain an ongoing conversation with their prescriber about supply reliability and contingency plans.

Given the 2023-2024 GLP-1 compounding enforcement precedent, any woman using AOD-9604 specifically for weight or adipose management should also discuss whether a GLP-1 receptor agonist (semaglutide, tirzepatide) represents a better-evidenced alternative. The STEP 1 trial demonstrated 14.9% mean body weight reduction with semaglutide 2.4 mg weekly over 68 weeks, a magnitude of effect that AOD-9604 has never demonstrated in a completed human trial.